Literature DB >> 2345906

Changes in ocular onchocerciasis four and twelve months after community-based treatment with ivermectin in a holoendemic onchocerciasis focus.

K Y Dadzie1, J Remme, E S Alley, G de Sole.   

Abstract

The impact of ivermectin mass treatment on ocular onchocerciasis was studied in a holoendemic focus of blinding onchocerciasis in Ghana. A cohort of 417 persons, 369 of whom were treated, was followed up at 4 and 12 months after treatment. The mean ocular microfilarial load in the anterior chamber of the eye and in the cornea of treated persons was reduced to less than 20% and 10% of the pretreatment levels respectively at the 4 months follow-up but had increased significantly by 12 months. Lesions of the eye at the advanced stage of development remained stable. There was significant regression of early lesions of the anterior segment of the eye, particularly iridocyclitis, after ivermectin treatment. In view of the substantial increase of ocular microfilarial loads after 12 months, 6-monthly treatment may be indicated in such highly endemic foci. However, long-term observation is needed to give a correct estimate of the full benefit to be derived from mass treatment with ivermectin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2345906     DOI: 10.1016/0035-9203(90)90395-u

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  5 in total

1.  Impact of annual dosing with ivermectin on progression of onchocercal visual field loss.

Authors:  S N Cousens; A Cassels-Brown; I Murdoch; O E Babalola; D Jatau; N D Alexander; J E Evans; P Danboyi; A Abiose; B R Jones
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

Review 2.  Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis.

Authors:  K L Goa; D McTavish; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

3.  Onchocerciasis in Ecuador: evolution of chorioretinopathy after amocarzine treatment.

Authors:  P J Cooper; R Proaño; C Beltran; M Anselmi; R H Guderian
Journal:  Br J Ophthalmol       Date:  1996-04       Impact factor: 4.638

Review 4.  Treatment of onchocerciasis.

Authors:  Y Van Laethem; C Lopes
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

Review 5.  Points of action in the campaign against blindness in developing countries.

Authors:  J S Stilma; S Franken; M Hogeweg; P Hardus
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.